ONEOK's Second 2026 Guidance Raise and Brazos Deal Strengthen Growth Case but Leverage Still Key

What happened

ONEOK raised full-year 2026 guidance for the second time, citing strong Q2 results and the $4.425B Brazos Midstream acquisition, with adjusted EBITDA now guided to $8.35B and EPS to $5.68. The announcement follows a period of stock underperformance that compressed forward P/E to ~14.75x, despite management's sustained delivery on EBITDA growth and integration synergies. The Brazos deal is described as accretive and structured to reduce net debt while preserving share count, though specifics on funding and leverage impact require verification in future filings. With major projects like Bighorn, Eiger, and Texas City nearing completion and a constructive macro backdrop for Permian and Rockies volumes, the operational growth thesis remains intact. However, the high payout ratio and still-elevated net debt/EBITDA of ~4.8x mean that the margin of safety hinges on execution, deleveraging, and avoiding further commodity-driven estimate cuts.

Implication

For investors, the second guidance raise and Brazos deal reinforce the potential for high-single-digit total returns if execution matches management's projections, with the compressed valuation offering an attractive entry near current levels. The key upside will come from EBITDA growth translating into faster deleveraging toward the 3.5x target, which could re-rate the stock from its current bond-proxy multiple. However, the still-elevated net debt/EBITDA of ~4.8x and near-breakeven free cash flow after capex and dividends mean the thesis remains sensitive to any operational slippage or commodity weakness. Investors should verify the Brazos funding structure and its actual impact on net debt before assuming balance sheet improvement. A prudent approach is to hold or initiate a modest position while monitoring quarterly leverage metrics and project milestones.

Thesis delta

The thesis strengthens modestly as management's second guidance raise and accretive Brazos acquisition validate the growth and deleveraging trajectory, pushing fair value toward the higher end of the $85-$95 range. However, until the funding details confirm net debt reduction and free cash flow improves, the conviction level remains unchanged at 3.5, with the attractive entry zone unchanged near $72. The key delta is an increased probability of the bull scenario (now ~25% from 20%) if leverage falls below 4.0x by year-end 2026.